Nankivell, Paul, Weller, Matthew, McConkey, Christopher C., Paleri, Vinidh and Mehanna, Hisham M.. (2011) Biomarkers in laryngeal dysplasia : a systematic review. Head & Neck, Vol.33 (No.8). pp. 1170-1176. ISSN 10433074

Full text not available from this repository.

Abstract

Background. Prediction of which laryngeal dysplasia cases will progress to cancer is poorly achieved. The differential expression of biomarkers in dysplastic and cancerous lesions may help to improve this. Methods. We carried out a systematic review of laryngeal dysplasia biomarkers. Risk ratios were calculated for each biomarker. Individual study data were pooled only for the biomarker p53. Results. In all, 286 potential studies were identified; 9 met the inclusion criteria with 13 biomarkers assessed. Relative risks ranged from 0.60 (95% confidence interval [Cl] 0.10, 3.75) for mdm2 to 84.55 (95% Cl 5.30, 1348.56) for Cortactin. A meta-analysis of studies using p53 failed to show this biomarker having a significant predictive ability. Conclusions. Currently there is no good evidence for the use of biomarkers in predicting the future behavior of laryngeal dysplastic lesions. Only 3 studies showed statistically significant results. Better reporting of studies using the REMARK (REporting recommendations for tumor MARKer prognostic studies) consensus guidelines should help to improve this in the future

Item Type:	Journal Article
Subjects:	R Medicine > R Medicine (General) R Medicine > RC Internal medicine
Divisions:	Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH):	Dysplasia, Biochemical markers, Systematic reviews (Medical research)
Journal or Publication Title:	Head & Neck
Publisher:	John Wiley & Sons Ltd.
ISSN:	10433074
Date:	August 2011
Volume:	Vol.33
Number:	No.8
Page Range:	pp. 1170-1176
Identification Number:	10.1002/hed.21592
Status:	Peer Reviewed
Publication Status:	Published
References:	1. Bouquot J, Gnepp D. Laryngeal precancer: a review of the literature, commentary, and comparison with oral leukoplakia. Head Neck 1991;13:488–497. 2. Minni A, Barbaro M, Rispoli G, Diaferia F, Bernardeschi D, Filipo R. Treatment with laser CO2 cordectomy and clinical implications in management of mild and moderate laryngeal precancerosis. Eur Arch Otorhinolaryngol 2008;265:189–193. 3. Sampedro A, Alvarez C, Suarez C, Nistal A. Quantitative pathology of the intraepithelial laryngeal neoplasia. Otolaryngol Head Neck Surg 1994;110:185–194. 4. Weller MD, Nankivell PC, McConkey CC, Paleri V, Mehanna H. The risk and interval to malignancy of patients with laryngeal dysplasia; a systematic review of case series and meta-analysis. Accepted for publication in Clin Otolaryngol doi: 10.1111/j.1749– 4486.2010.02181.x 5. Gale N, Michaels L, Luzar B, et al. Current review on squamous intraepithelial lesions of the larynx. Histopathology 2009;54: 639–656. 6. McLaren K, Burnett R, Goodlad J, et al. Consistency of histopathological reporting of laryngeal dysplasia. The Scottish Pathology Consistency Group. Histopathology 2000;37:460–463. 7. Fleskens S, Slootweg P. Grading systems in head and neck dysplasia: their prognostic value, weaknesses and utility. Head Neck Oncol 2009;1:11 (abstract). 8. Stroup D, Berlin J, Morton S, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008–2012. 9. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 2003;73:712–716. 10. Yildiz N, Akcil M, Tez M. A comparison of the effect size estimators in meta-analysis. Appl Math Sci 2009;3:715–724. Table 5. Pooled relative risks for p53 with sensitivity analysis. % cell staining used to classify negative biomarker group Pooled RR (95% CI) Heterogeneity Q (df) p value 0% (2 studies) 2.13 (0.71, 6.39) Q ¼ 0.01 (1) p ¼ .92 <5% (3 studies) 2.49 (0.90, 6.91) Q ¼ 0.57 (1) p ¼ .75 <10% (4 studies) 1.78 (0.73, 4.34) Q ¼ 2.35 (1) p ¼ .50 <25% (5 studies) 1.42 (0.20, 10.12) Q ¼ 7.50 (1) p ¼ .10 Abbreviations: RR, relative risk; CI, confidence interval; df, degrees of freedom. 11. Azzimonti B, Hertel L, Aluffi P, et al. Demonstration of multiple HPV types in laryngeal premalignant lesions using polymerase chain reaction and immunohistochemistry. J Med Virol 1999; 59:110–116. 12. Capaccio P, Pruneri G, Carboni N, et al. Cyclin D1 protein expression is related to clinical progression in laryngeal squamous cell carcinomas. J Laryngol Otol 1997;111:622–626. 13. Chi FL, Yuan YS, Wang SY, Wang ZM. Study on ceramide expression and DNA content in patients with healthy mucosa, leukoplakia, and carcinoma of the larynx. Arch Otolaryngol Head Neck Surg 2004;130:307–310. 14. Fan G, Xu F, Yang B, Fujieda S. p57(kip2) expression is related to carcinogenesis and tumor progression in laryngeal tissues. Acta Otolaryngol 2006;126:301–305. 15. Fraczek M, Wozniak Z, Ramsey D, Krecicki T. Expression patterns of cyclin E, cyclin A and CDC25 phosphatases in laryngeal carcinogenesis. Eur Arch Oto-Rhino-Laryngol 2007;264:923–928. 16. Gallo O, Franchi A, Chiarelli I, et al. Potential biomarkers in predicting progression of epithelial hyperplastic lesions of the larynx. Acta Oto-Laryngol Suppl 1997;527:30–38. 17. Garozzo A, Cutrona D, Palmeri S, Maiolino L, Puzzo L, Allegra E. The role of p53 tumor suppressor gene as prognostic factor in laryngeal squamous cell carcinoma [in Italian]. Acta Otorhinolaryngol Ital 1999;19:342–347. 18. Guler G, Sarac¸ S, Uner A, Karabulut E, Ayhan A, Hiroshi O. Prognostic value of CD44 variant 6 in laryngeal epidermoid carcinomas. Arch Otolaryngol Head Neck Surg 2002;128:393–397. 19. Hellquist H, Olofsson J. Expression of low molecular weight cytokeratin proteins in laryngeal dysplasia. APMIS 1988;96:971– 978. 20. Hirvikoski P, Tammi R, Kumpulainen E, et al. Irregular expression of hyaluronan and its CD44 receptor is associated with metastatic phenotype in laryngeal squamous cell carcinoma. Virchows Arch 1999;434:37–44. 21. Ioachim E, Assimakopoulos D, Agnantis N, Peschos D, Zissi A, Skevas A. Altered patterns of retinoblastoma gene product expression in benign, premalignant and malignant epithelium of the larynx: an immunohistochemical study including correlation with p53, bcl-2 and proliferating indices. Anticancer Res 1999;19:541–545. 22. Izzo J, Papadimitrakopoulou V, Liu D, et al. Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J Natl Cancer Inst 2003;95:198–205. 23. Jeannon J, Soames J, Aston V, Stafford F, Wilson J. Molecular markers in dysplasia of the larynx: expression of cyclin-dependent kinase inhibitors p21, p27 and p53 tumour suppressor gene in predicting cancer risk. Clin Otolaryngol Allied Sci 2004;29:698–704. 24. Krecicki T, Jelen´ M, Zalesska-Krecicka M, Szkudlarek T, Szajowski K. Immunohistochemically stained markers (p53, PCNA, bcl- 2) in dysplastic lesions of the larynx. Cancer Lett 1999;143:23– 28. 25. Maiorano E, Botticella M, Marzullo A, Resta L. Expression of ERD5 and EGFr in laryngeal carcinoma and pre-malignant epithelium. Acta Otolaryngol Suppl 1997;527:95–99. 26. Mirza S, Jeannon JP, Soames J, Wilson JA. Is Ki67 a marker for the transformation of laryngeal dysplasia to carcinoma? Acta Oto-Laryngol 2006;126:418–422. 27. Munck-Wikland E, Edstro¨m S, Jungmark E, Kuylenstierna R, Lindholm J, Auer G. Nuclear DNA content, proliferating-cell nuclear antigen (PCNA) and p53 immunostaining in predicting progression of laryngeal cancer in situ lesions. Int J Cancer 1994;56:95–99. 28. Munck-Wikland E, Kuylenstierna R, Lindholm J, Auer G. p53 immunostaining and image cytometry DNA analysis in precancerous and cancerous squamous epithelial lesions of the larynx. Head Neck 1997;19:107–115. 29. Munck-Wikland E, Heselmeyer K, Lindholm J, Kuylenstierna R, Auer G, Engel G. Stromelysin-3 mRNA expression in dysplasias and invasive epithelial cancer of the larynx. Int J Oncol 1998;12:859–864. 30. Nadal A, Campo E, Pinto J, et al. p53 expression in normal, dysplastic, and neoplastic laryngeal epithelium. Absence of a correlation with prognostic factors. J Pathol 1995;175:181–188. 31. Papadimitrakopoulou V, Liu D, Mao L, et al. Biologic correlates of a biochemoprevention trial in advanced upper aerodigestive tract premalignant lesions. Cancer Epidemiol Biomarkers Prev 2002;11:1605–1610. 32. Papadimitrakopoulou V, Izzo J, Liu D, et al. Cyclin D1 and cancer development in laryngeal premalignancy patients. Cancer Prev Res 2009;2:14–21. 33. Peschos D, Damala C, Stefanou D, et al. Expression of matrix metalloproteinase-9 (gelatinase B) in benign, premalignant and malignant laryngeal lesions. Histol Histopathol 2006;21:603– 608. 34. Pignataro L, Capaccio P, Pruneri G, et al. The predictive value of p53, MDM-2, cyclin D1 and Ki67 in the progression from lowgrade dysplasia towards carcinoma of the larynx. J Laryngol Otol 1998;112:455–459. 35. Rho YS, Lim YC, Park IS, et al. High mobility group HMGI(Y) protein expression in head and neck squamous cell carcinoma. Acta Oto-Laryngol 2007;127:76–82. 36. Rodrigo J, Garcı´a-Carracedo D, Garcı´a L, et al. Distinctive clinicopathological associations of amplification of the cortactin gene at 11q13 in head and neck squamous cell carcinomas. J Pathol 2009;217:516–523. 37. Sanz-Ortega J, Valor C, Saez M, et al. 3p21, 5q21, 9p21 and 17p13 allelic deletions accumulate in the dysplastic spectrum of laryngeal carcinogenesis and precede malignant transformation. Histol Histopathol 2003;18:1053–1057. 38. Saussez S, Decaestecker C, Lorfevre F, et al. Increased expression and altered intracellular distribution of adhesion/growth-regulatory lectins galectins-1 and -7 during tumour progression in hypopharyngeal and laryngeal squamous cell carcinomas. Histopathology 2008;52:483–493. 39. Shigyo H, Nonaka S, Katada A, et al. Inducible nitric oxide synthase expression in various laryngeal lesions in relation to carcinogenesis, angiogenesis, and patients’ prognosis. Acta Otolaryngol 2007;127:970–979. 40. Sprinzl G, Hussl B, Obrist P, et al. Dendritic cells in precancerous lesions of the larynx. Laryngoscope 2000; 110:13–18. 41. Staibano S, Merolla F, Testa D, et al. OPN/CD44v6 overexpression in laryngeal dysplasia and correlation with clinical outcome. Br J Cancer 2007;97:1545–1551. 42. Suga´r J, Vereczkey I, To´th J, Pe´ter I, Ba´nhidy F. New aspects in the pathology of the preneoplastic lesions of the larynx. Acta Otolaryngol Suppl 1997;527:52–56. 43. Yuan Y, Chi F, Wang S, Wang Z. Significance of ceramide and DNA ploidy in laryngeal carcinogenesis. ORL J Otorhinolaryngol Relat Spec 2007;69:283–288. 44. Zhao R, Hirano M, Kurita S. Expression of proliferating cell nuclear antigen in premalignant lesions of the larynx. Am J Otolaryngol 1996;17:36–44. 45. Silvestri F, Bussani R, Pavletic N, Mannone T, Bosatra A. From epithelial dysplasia to squamous carcinoma of the head and neck region: evolutive and prognostic histopathological markers. Acta Otolaryngol Suppl 1997;527:49–51. 46. McShane L, Altman D, Sauerbrei W, Taube S, Gion M, Clark G. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005;93:387–391.
URI:	http://wrap.warwick.ac.uk/id/eprint/38573

Data sourced from Thomson Reuters' Web of Knowledge

Request changes to a record

Actions (login required)

View Item